Skip to main content

Appili Therapeutics Inc(APLI-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0200
Day High0.0200
Open:0.0200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Appili Therapeutics Inc
GlobeNewswire
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Baystreet
Stocks in play: Appili Therapeutics Inc.
GlobeNewswire
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
GlobeNewswire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
GlobeNewswire
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
GlobeNewswire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
GlobeNewswire
Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Baystreet
Stocks in play: Appili Therapeutics Inc.
GlobeNewswire
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
GlobeNewswire
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
GlobeNewswire
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
GlobeNewswire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
GlobeNewswire
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
GlobeNewswire
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
Baystreet
Stocks in play: Appili Therapeutics Inc.
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
GlobeNewswire
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
Baystreet
Stocks in play: Appili Therapeutics Inc.
GlobeNewswire
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
Baystreet
Stocks in play: Appili Therapeutics Inc.
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
GlobeNewswire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (APLI)
AI-generated - The Globe and Mail
Appili Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (APLI)
GlobeNewswire
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
GlobeNewswire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Profile

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.